Arix Bioscience
plc
2019 Capital
Markets Day
Oncology Portfolio Spotlight
LONDON, 3 October 2019: Arix Bioscience plc (“Arix”,
LSE: ARIX) a global venture capital company focused on investing in
and building breakthrough biotech companies, is hosting its 2019
Capital Markets Day from 1:45pm today
Thursday, 3rd October 2019
in London.
The Capital Markets Day, focused on Arix’s oncology portfolio,
will be an opportunity for institutional investors, analysts and
media to learn more about Arix, its portfolio companies and
strategy.
The event will include presentations from
Joe Anderson, Chief Executive Officer and Jonathan Tobin,
Investment Director, along with presentations from
the oncology portfolio companies, a panel discussion and
Q&A.
No new material information will be disclosed.
Presenters at the Arix Capital Markets
Day will include:
-
Joe Anderson, PhD, CEO of Arix
Bioscience plc
-
Jonathan Tobin, PhD, Investment
Director, Arix Bioscience plc
-
Christian Schetter, PhD,
Entrepreneur in Residence, Arix Bioscience plc and Executive
Chairman, STipe Therapeutics
-
Elisabet de los Pinos, PhD, CEO
of Aura Biosciences
-
Christian Itin, PhD, CEO and
Chairman of Autolus (NASDAQ: AUTL)
-
Dave Johnson, President and CEO
of VelosBio
-
Niall Martin, PhD, CEO of Artios
Pharma
- Gerald McMahon, PhD, President
and CEO of Harpoon Therapeutics (NASDAQ: HARP)
Event details
Registration for the event will start at 1:45pm BST followed by a series of presentations
and Q&A sessions starting promptly from 2:10pm BST. The day will conclude with a
networking session from approximately 5:30pm
BST.
A webcast of the event, with presentation slides, will be
available on the Arix website after the event.
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor
Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Supriya Mathur
T: +44 (0) 203 950 9144
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused
on investing in and building breakthrough biotech companies around
cutting edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the
capital, expertise and global networks to help accelerate their
ideas into important new treatments for patients. As a listed
company, we are able to bring this exciting growth phase of our
industry to a broader range of investors.
www.arixbioscience.com